BOSTON — No one expected a new oral anticoagulant (NOAC) comparison with warfarin featuring "real-world" data from patients with atrial fibrillation (AF) to turn clinical trial results on their head.
The European Heart Rhythm Association (EHRA) has come out with the fourth iteration of its practical guide on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback